Venue: Medicon Village, Lund
Time: 8:45 - 15:30
For the sixth year in a row you are invited to interact around research and innovation in the oncology area. How can new ideas be created by working cross borders? How can industry, academia and healthcare sector work together?
Key note speaker of the 2019 meeting:
Professor Joseph P. Schlessinger, Yale University, New Haven, Connecticut
Professor Schlessinger is a pioneer within the area of growth factor signalling and has published numerous articles in the area of the FGF-receptor and its mechanism of activation and signaling, but also work relating to growth factor receptors, such as the EGFR and KIT. He is among the most highly cited scientists within this field of research. Professor Schlessinger has also been co-founder in several biotech companies. Among those, SUGEN (now part of Pfizer; was one of the first companies to develop several targeted tyrosine kinase inhibitors for cancer treatment), Plexxikon (now part of Daiichi-Sankyo, developed the first BRAF inhibitor for treatment of malignant melanoma) and Kolltan Pharmaceuticals that develops therapeutic antibodies against receptor tyrosine kinases.
Apart from the key note session, the successful topics from previous years, as
If you wish to be part of and have questions or topics you’d like to bring up for the Dialogue forums, please contact: email@example.com.